Antheia and Olon Extend Partnership for Biomanufacturing Essential Raw Materials and Active Pharmaceutical Ingredients
Thursday, March 14, 2024
Antheia, a company focused on revolutionizing essential medicines supply chains through innovative pharmaceutical ingredients, has announced a partnership with Olon Group, a prominent player in the development and manufacturing of active pharmaceutical ingredients (APIs). This collaboration aims to utilize Olon's fermentation infrastructure to produce Antheia's first-generation products.
Formed in 2022, the partnership between Antheia and Olon centers on utilizing Olon's fermentation sites in Italy. Olon has been instrumental in scaling Antheia's biomanufacturing processes and producing its biosynthetic MPEs and APIs. Antheia plans to continue this collaboration to expand capacity and meet the increasing international demand for its first-generation products, including thebaine.
Zack McGahey, Chief Operating Officer of Antheia, highlighted the importance of selecting the right partner for their commercialization journey. He emphasized Olon's reputation for quality pharmaceutical products and efficiency, making them an ideal partner for Antheia's goals. Both companies look forward to delivering their first-generation products later this year and transforming essential medicines supply chains.
Olon Biotech, a division of Olon Group, brings over 50 years of experience in fermentation manufacturing services. With a fermentation capacity of 5,000 cubic meters across its sites, Olon is a leading international CDMO for biomanufacturing. Maurizio Sartorato, Vice President of Olon Biotech, underscored Olon's investments in biotechnology centers to increase production capacity, enhance efficiency, and reduce environmental impact.
The partnership between Antheia and Olon signifies a promising future for pharmaceutical supply chains, driven by innovation, quality, and sustainability. Both companies remain committed to making a positive impact in the industry.
Source: globenewswire.com
